ClinicalTrials.gg
CompletedNCT05887999Updated Mar 26, 2024

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of LY3532226 and Placebo in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.

Enrollment
48th of 72
30 · median 62
Started
2023
with 1 other
Phase 1
33 of 75
2 open now
Registered
67th of 75
by date

Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 48th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2023, is one of 33 in phase 1, and was the 67th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
  • (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
  • Are males or females not of

Exclusion criteria

Exclusion Criteria:

  • Have acute proliferative retinopathy requiring active treatment within 3 months of screening
  • Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
  • Have received systemic or inhaled therapy
  • Women of
  • Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    LY3532226

    Drug: LY3532226

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered subcutaneously (SC).

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia

    PD: AUC60-120min of plasma glucagon during the insulin-induced hypoglycemia

    Time frame: Predose up to 120 mins postdose

Secondary outcomes

  1. The amount of exogenous glucose infused to maintain a plasma glucose level of >2.5 millimole per liter (mmol/L), after the insulin infusion is terminated.

    The amount of exogenous glucose infused to maintain a plasma glucose level of \>2.5 mmol/L, after the insulin infusion is terminated.

    Time frame: Predose up to 120 mins postdose

  2. Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT)

    Change from Baseline in Fasting and Post meal Glucose during sMMTT

    Time frame: Predose up to 120 mins postdose

  3. Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT

    Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT

    Time frame: Predose up to 120 mins postdose

07

Study locations

1 site
  • ProSciento, Inc
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Feb 2024, 8 months.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 8 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 5, 2023
StartActual
Jun 12, 2023
Primary completionActual
Feb 21, 2024
CompletionActual
Feb 21, 2024
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05887999
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Jun 12, 2023
Primary completion
Feb 21, 2024
Completion
Feb 21, 2024
Last update
Mar 26, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Macupatide

Start the discussion